XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.2
REVENUES - Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]        
Total revenues $ 7,421 $ 6,577 $ 20,061 $ 17,268
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,509 5,100 14,002 12,890
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,031 937 3,559 2,698
Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 881 540 2,500 1,680
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 7,356 6,493 19,848 17,027
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,479 5,076 13,932 12,835
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 997 877 3,419 2,528
Total product sales | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 880 540 2,497 1,664
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 4,189 4,547 11,777 12,681
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 3,302 3,722 9,132 10,213
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 602 569 1,776 1,720
Total HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 285 256 869 748
Atripla        
Disaggregation of Revenue [Line Items]        
Total revenues 27 113 118 311
Atripla | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 21 99 96 275
Atripla | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 2 5 10 17
Atripla | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 9 12 19
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 2,276 1,891 6,094 5,188
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 1,875 1,584 4,926 4,346
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 254 194 707 528
Biktarvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 147 113 461 314
Complera/Eviplera        
Disaggregation of Revenue [Line Items]        
Total revenues 64 70 189 218
Complera/Eviplera | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 28 26 73 77
Complera/Eviplera | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 31 35 104 124
Complera/Eviplera | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 5 9 12 17
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 433 508 1,227 1,383
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 355 424 994 1,124
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 42 49 128 156
Descovy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 36 35 105 103
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 744 846 2,123 2,486
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 576 669 1,633 1,927
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 100 116 306 376
Genvoya | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 68 61 184 183
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 399 437 1,148 1,228
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 275 309 773 851
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 112 116 336 341
Odefsey | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 12 12 39 36
Stribild        
Disaggregation of Revenue [Line Items]        
Total revenues 42 42 139 154
Stribild | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 28 27 94 100
Stribild | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 11 13 33 42
Stribild | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 2 12 12
Truvada        
Disaggregation of Revenue [Line Items]        
Total revenues 67 509 310 1,302
Truvada | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 55 492 268 1,245
Truvada | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 6 18 20
Truvada | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 7 11 24 37
Revenue share - Symtuza        
Disaggregation of Revenue [Line Items]        
Total revenues 130 118 394 362
Revenue share - Symtuza | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 86 82 261 244
Revenue share - Symtuza | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 41 34 125 112
Revenue share - Symtuza | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 2 8 6
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 7 13 35 49
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 3 10 14 24
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 4 1 9 4
Other HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 2 12 21
Total HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 429 464 1,488 1,641
Total HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 224 241 809 859
Total HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 94 98 322 316
Total HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 111 125 357 466
Ledipasvir/Sofosbuvir        
Disaggregation of Revenue [Line Items]        
Total revenues 45 84 163 263
Ledipasvir/Sofosbuvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 14 36 63 113
Ledipasvir/Sofosbuvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 11 24 26
Ledipasvir/Sofosbuvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 26 37 76 124
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 332 330 1,155 1,229
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 173 170 649 646
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 77 74 234 253
Sofosbuvir/Velpatasvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 82 86 272 330
Other HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 52 50 170 149
Other HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 37 35 97 100
Other HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 12 13 64 37
Other HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 2 9 12
Total HBV/HDV        
Disaggregation of Revenue [Line Items]        
Total revenues 247 211 704 616
Total HBV/HDV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 104 102 275 267
Total HBV/HDV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 29 18 76 55
Total HBV/HDV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 114 91 353 294
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 208 177 589 464
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 103 99 266 248
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 9 8 25 22
Vemlidy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 96 70 298 194
Viread        
Disaggregation of Revenue [Line Items]        
Total revenues 26 32 85 137
Viread | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 1 3 8 10
Viread | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 7 8 22 27
Viread | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 18 21 55 100
Other HBV/HBD        
Disaggregation of Revenue [Line Items]        
Total revenues 13 2 30 15
Other HBV/HBD | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 1 9
Other HBV/HBD | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 13 2 29 6
Other HBV/HBD | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 1,923 873 4,208 873
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 1,527 785 2,763 785
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 109 60 761 60
Veklury | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 287 28 684 28
Total Cell Therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 222 147 632 444
Total Cell Therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 135 90 394 288
Total Cell Therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 78 55 213 149
Total Cell Therapy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 9 2 25 7
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 47 9 119 10
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 35 5 94 5
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 12 4 25 5
Tecartus | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 175 138 513 434
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 100 85 300 283
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 66 51 188 144
Yescarta | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 9 2 25 7
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 101 0 262 0
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 100 0 261 0
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1 0 1 0
Trodelvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Total Other        
Disaggregation of Revenue [Line Items]        
Total revenues 245 251 777 772
Total Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 87 136 298 423
Total Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 84 77 270 228
Total Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 74 38 209 121
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 143 111 420 325
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 7 18 32 46
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 67 58 202 166
AmBisome | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 69 35 186 113
Letairis        
Disaggregation of Revenue [Line Items]        
Total revenues 46 78 157 241
Letairis | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 46 78 157 241
Letairis | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Letairis | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Ranexa        
Disaggregation of Revenue [Line Items]        
Total revenues     5 9
Ranexa | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues     5 9
Ranexa | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues     0 0
Ranexa | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues     0 0
Zydelig        
Disaggregation of Revenue [Line Items]        
Total revenues 13 17 50 55
Zydelig | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 6 8 22 24
Zydelig | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 7 9 27 30
Zydelig | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 1 1
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 43 45 145 142
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 28 32 82 103
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 10 10 41 32
Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 5 3 22 7
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 65 84 213 241
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 30 24 70 55
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 34 60 140 170
Royalty, contract and other revenues | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1 $ 0 $ 3 $ 16